Compare Endeavour Silver Corp (EXK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Novo Nordisk A/S — how do they compare? Endeavour Silver Corp trades at $10.71 (market cap $3.14B), while Novo Nordisk A/S trades at $46.04 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 66.2× Endeavour Silver Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | NVO | |
|---|---|---|
Market Cap | $3.14B | $207.85B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $63.98 |
52-Week Low | $5.31 | $35.29 |
Enterprise Value | $3.14B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $10.68, up 4.3% today, with a bullish technical outlook driven by moving averages and strong analyst sentiment. The company reported Q2 2026 earnings in line with estimates at $0.15 per share, with revenue growth and operational execution highlighted in recent news. Financials show improving trends, with 2026 revenue projected at $737 million and net income turning positive to $66 million, though 2025 saw a net loss of $119 million. A new $25 million credit facility was secured in August 2026, supporting liquidity.
The stock offers upside to the consensus price target of $15.50, with 79% of analysts rating it Buy. Key risks include volatile silver prices, execution challenges at new mines, and high valuation multiples like a P/E of 52.95. Positive catalysts include production ramp-ups and favorable metal price outlooks, but investors should monitor debt levels and commodity cycles.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
